An extended study: protective effects of nerve growth factor in neomycin-induced auditory neural degeneration.
Intracochlear survival of auditory neurons is thought to be a factor contributing to the success of cochlear implantations. Damage to the cochlear end-organ is frequently associated with loss of neurites in the osseous spiral lamina. The authors have previously reported a model for long-term intracochlear administration of pharmacologic agents using a technique and device analogous to a cochlear implant. These studies suggest that nerve growth factor (NGF) protects the auditory nerve from the immediate neurotoxic effects of neomycin. The intent of the present investigation is to determine whether NGF can protect auditory neural elements from neomycin-induced degeneration after several weeks have elapsed between the neomycin perfusion and the administration of NGF. Neomycin was infused over 24 hours through an indwelling, intracochlear cannula attached to a mini osmotic pump to unilaterally destroy the cochlear end-organ. The pump perfused the cochlea with artificial perilymph for 2 weeks. Then, the pump reservoirs were surgically replaced; the new reservoirs delivered either NGF or artificial perilymph for an additional 2 weeks. Spiral ganglion cell densities were measured along Rosenthal's canal in the basal, middle, and apical cochlear turns. This investigation revealed that NGF prevented auditory nerve degeneration over the 2-week period, when compared to controls, and that the protective effect was greatest in the neural elements closest to the source of NGF.
Shah
S B
SB
Department of Otolaryngology--Head and Neck Surgery, Epstein Hearing Research Laboratory, University of California, San Francisco, USA.
Gladstone
H B
HB
Williams
H
H
Hradek
G T
GT
Schindler
R A
RA
D000818:Animals; D000900:Anti-Bacterial Agents; D003051:Cochlea / Q000187:drug effects; D004195:Disease Models, Animal; D006168:Guinea Pigs; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D009355:Neomycin; D009410:Nerve Degeneration / Q000187:drug effects*; D009414:Nerve Growth Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D010477:Perfusion; D013136:Spiral Ganglion / Q000187:drug effects* / Q000473:pathology; D000159:Vestibulocochlear Nerve / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D009414:Nerve Growth Factors; D009355:Neomycin